Moteur de recherche d’entreprises européennes
Financement de l’UE (6 000 000 €) : CIRRHOSE DÉCOMPENSÉE : IDENTIFICATION DE NOUVELLES THÉRAPIES COMBINATOIRES BASÉES SUR DES APPROCHES SYSTÉMIQUES Hor13/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
CIRRHOSE DÉCOMPENSÉE : IDENTIFICATION DE NOUVELLES THÉRAPIES COMBINATOIRES BASÉES SUR DES APPROCHES SYSTÉMIQUES
In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. This mortality is mainly due to cirrhosis decompensation, i.e. development of ascites, hepatic encephalopathy, and/or gastrointestinal hemorrhage, and its progression to acute-on-chronic liver failure (ACLF). Patients with decompensated cirrhosis receive many treatments such as intravenous and oral absorbable antibiotics, oral non-absorbable antibiotics, albumin, proton-pump inhibitors, laxatives, diuretics, betablockers, vasoconstrictors, statins, anticoagulants, steroids and antiviral agents. Despite these multiple treatments, ACLF or mortality in patients with decompensation of cirrhosis remains high (15% at day 28, 28% at day 90) because of large interindividual variability in precipitating events, in clinical presentation and in response to treatment. This heterogeneity calls for treatment personalization according to underlying mechanisms. The objective of DECISION is to enhance our understanding, at systems level, of the pathophysiology of decompensation of cirrhosis leading to ACLF or death to decrease patients’ mortality at day 28. First, DECISION will improve our knowledge of the pathophysiology of decompensation of cirrhosis by integrating results of high-throughput multi-omic profiling with comprehensive clinical data from 2,200 fully characterized patients (more than 8,600 time points) with available standardized biological samples. Second, we will identify novel combinatorial therapies for patients with decompensation of cirrhosis to prevent death. We will refine these therapies in new and/or optimized animal models and then test the best combination in high risk patients in a phase II clinical trial built in DECISION. Third, we will develop 2 tests: one predicting outcome of patients with decompensation of cirrhosis when treated with standard treatment (prognostic test); and the other identifying patients who will respond to the novel combinatorial therapy (test for response).
| Alma Mater Studiorum - Universita DI Bologna | 171 722 € |
| Assistance Publique Hopitaux de Paris | 420 472 € |
| Azienda Ospedaliera Citta Della Salute E Della Scienza DI Torino | 0,00 € |
| CONCENTRIS RESEARCH MANAGEMENT GmbH | 488 500 € |
| Commissariat a L Energie Atomique et aux Energies Alternatives | 345 000 € |
| EUROPEAN Association FOR THE STUDYOF THE LIVER | 50 000 € |
| Erasmus Universitair Medisch Centrum Rotterdam | 300 000 € |
| 1 233 650 € | |
| European Liver Patients Association | 50 000 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 371 722 € |
| 382 500 € | |
| Hospital Clinic de Barcelona | 0,00 € |
| 105 472 € | |
| Institut National de la Sante et de la Recherche Medicale | 620 500 € |
| 0,00 € | |
| JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN | 257 692 € |
| Nordic Bioscience A/S | 66 043 € |
| 105 472 € | |
| UNIVERSITAET MUENSTER | 121 530 € |
| UNIVERSITAETSKLINIKUM AACHEN | 275 874 € |
| Universita Degli Studi DI Padova | 42 500 € |
| Universita Degli Studi DI Torino | 105 472 € |
| Universitat de Barcelona | 120 000 € |
| Universite Paris Cite | 0,00 € |
| 105 879 € | |
| YH Youhealth AB | 260 000 € |
https://cordis.europa.eu/project/id/847949
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Alma Mater Studiorum - Universita DI Bologna - Financement de l’UE (6 000 000 €) : CIRRHOSE DÉCOMPENSÉE : IDENTIFICATION DE NOUVELLES THÉRAPIES COMBINATOIRES BASÉES SUR DES APPROCHES SYSTÉMIQUES"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
